Phase 1 study of REGN1400 (anti-ErbB3) combined with erlotinib or cetuximab in patients (pts) with advanced non-small cell lung cancer (NSCLC), colorectal cancer (CRC), or head and neck cancer (SCCHN).
Kyriakos P. Papadopoulos
Research Funding - Regeneron
Alex A. Adjei
Research Funding - Regeneron
Drew Warren Rasco
Research Funding - Regeneron
Liming Liu
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Richard J. Kao
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Carrie M. Brownstein
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
A Thomas DiCioccio
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Israel Lowy
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Pamela Trail
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Ding Wang
Research Funding - Regeneron